Research Question:Neuropsychiatric disorders affect 1 in 4 people globally, while neurological disorders are the second leading cause of death in the elderly (WHO, 2001; GBD 2016 Neurology Collaborators, 2019). Despite this burden, their pathogenesis remains poorly understood, effective biomarkers for diagnosis/prognosis are lacking, and personalized treatments remain unavailable.
Objective:This study integrates genetic, metabolomic, proteomic, and epidemiological data to identify novel risk factors, biomarkers, and causal mechanisms underlying neuropsychiatric disorders through multidimensional analysis.
Scientific Rationale:While prior single-omics studies (genome/metabolome/proteome) have identified disease-associated differences, their isolated focus limits mechanistic insights. We will combine multi-omics (proteomics/metabolomics) with epidemiological data to:Validate known observational associations;Discover new risk factors/biomarkers;Elucidate causal pathways across 16+ neuropsychiatric conditions including:Cerebrovascular Diseases (stroke, aneurysm, transient ischemic attack, intracranial stenosis/occlusion, moyamoya);Neurodegenerative Diseases;Epilepsy & Paroxysmal Disorders; CNS Infections/Inflammation; Neuroimmunological Diseases; Brain Tumors; Traumatic Brain Injury & Related Disorders;Functional Neurological Disorders;Spinal Cord/Peripheral Nerve Diseases
